Advanced Renal Cell Carcinoma Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies by DelveInsight | AstraZeneca, Ipsen, Novartis, Merck Sharp & Dohme Corp., Pfizer, Bayer

The Advanced Renal Cell Carcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Advanced Renal Cell Carcinoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Advanced Renal Cell Carcinoma Market.

Some of the key takeaways from the Advanced Renal Cell Carcinoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Advanced Renal Cell Carcinoma treatment therapies with a considerable amount of success over the years. 
• Advanced Renal Cell Carcinoma companies working in the treatment market are Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang Therapeutics, CoImmune, Infinity Pharmaceuticals, Chia Tai TianqingPharmaceutical, Hoffmann-La Roche, and others, are developing therapies for the Advanced Renal Cell Carcinoma treatment 
• Emerging Advanced Renal Cell Carcinoma therapies such as – OATD-02, DS-6000a, JANX008, NKT2152, CMN-001, IPI-549, TQB2450, Belzutifan, Atezolizumab, and others are expected to have a significant impact on the Advanced Renal Cell Carcinoma market in the coming years.   
• In March 2022, In order to compare the effectiveness and safety of Belzutifan (MK-6482) plus pembrolizumab (MK-3475) versus placebo plus pembrolizumab in the adjuvant treatment of clear cell renal cell carcinoma (ccRCC) post-nephrectomy (MK-6482-022), Merck Sharp & Dohme started a multicenter, double-blind, randomised Phase III study
• The objective response rate (ORR) per investigator assessment was 57% among 35 treated patients at a median follow-up of 14.0 months, according to data presented at the ESMO Congress in 2022. The rates of complete response (CR), partial response (PR), and stable disease (SD) were 6%, 51%, and 37%, respectively
• In November 2021, Savolitinib (ORPATHYS® in China), an oral, powerful, and highly selective small-molecule inhibitor of MET, a receptor tyrosine kinase, was studied in combination with AstraZeneca’s PD-L1 inhibitor, IMFINZI® (durvalumab), in the SAMETA global Phase III study for patients with MET-driven advanced papillary renal cell carcinoma (“PRCC”)
• In August 2021, Exelixis, Inc. reported that the Japanese Ministry of Health, Labour and Welfare had granted permission for the manufacture and marketing of CABOMETYX in combination with OPDIVO® (nivolumab) as a treatment for metastatic or unresectable renal cell carcinoma (RCC). Takeda Pharmaceutical Company Limited (Takeda), its partner in charge of the clinical development and commercialization of CABOMETYX® (cabozantinib) in Japan, and Ono Pharmaceutical Co

Advanced Renal Cell Carcinoma Overview

Renal Cell Carcinoma (RCC) is the most prevalent form of kidney cancer, according to the Centres for Disease Control and Prevention (CDC) Trusted Source. The lining of the kidney’s tiny tubes, or tubules, is where this type of cancer grows. These tubules aid in the removal of waste from the circulation.

Get a Free Sample PDF Report to know more about Advanced Renal Cell Carcinoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-pipeline-insight

Emerging Advanced Renal Cell Carcinoma Drugs Under Different Phases of Clinical Development Include:

• OATD-02: Molecure S.A.
• DS-6000a: Daiichi Sankyo
• JANX008: Janux Therapeutics
• NKT2152: NiKang Therapeutics
• CMN-001: CoImmune
• IPI-549: Infinity Pharmaceuticals
• TQB2450: Chia Tai TianqingPharmaceutical
• Belzutifan: Merck Sharp & Dohme
• Atezolizumab: Hoffmann-La Roche

Route of Administration

Advanced Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Advanced Renal Cell Carcinoma Pipeline Therapeutics Assessment

• Advanced Renal Cell Carcinoma Assessment by Product Type
• Advanced Renal Cell Carcinoma By Stage and Product Type
• Advanced Renal Cell Carcinoma Assessment by Route of Administration
• Advanced Renal Cell Carcinoma By Stage and Route of Administration
• Advanced Renal Cell Carcinoma Assessment by Molecule Type
• Advanced Renal Cell Carcinoma by Stage and Molecule Type

DelveInsight’s Advanced Renal Cell Carcinoma Report covers around 5+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Advanced Renal Cell Carcinoma product details are provided in the report. Download the Advanced Renal Cell Carcinoma pipeline report to learn more about the emerging Advanced Renal Cell Carcinoma therapies

Some of the key companies in the Advanced Renal Cell Carcinoma Therapeutics Market include:

Key companies developing therapies for Advanced Renal Cell Carcinoma are – AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveo Pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others.

Advanced Renal Cell Carcinoma Pipeline Analysis:

The Advanced Renal Cell Carcinoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Renal Cell Carcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Renal Cell Carcinoma Treatment.
• Advanced Renal Cell Carcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Advanced Renal Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Renal Cell Carcinoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Advanced Renal Cell Carcinoma drugs and therapies

Advanced Renal Cell Carcinoma Pipeline Market Drivers

• Increasing Prevalence in Advanced Renal Cell Carcinoma, increase in the number of research and development activities are some of the important factors that are fueling the Advanced Renal Cell Carcinoma Market.

Advanced Renal Cell Carcinoma Pipeline Market Barriers

• However, side-effects associated with the treatment of Advanced Renal Cell Carcinoma, cost associated with the treatment and other factors are creating obstacles in the Advanced Renal Cell Carcinoma Market growth.

Scope of Advanced Renal Cell Carcinoma Pipeline Drug Insight    

• Coverage: Global
• Key Advanced Renal Cell Carcinoma Companies: Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang Therapeutics, CoImmune, Infinity Pharmaceuticals, Chia Tai TianqingPharmaceutical, Hoffmann-La Roche, and others
• Key Advanced Renal Cell Carcinoma Therapies: OATD-02, DS-6000a, JANX008, NKT2152, CMN-001, IPI-549, TQB2450, Belzutifan, Atezolizumab, and others
• Advanced Renal Cell Carcinoma Therapeutic Assessment: Advanced Renal Cell Carcinoma current marketed and Advanced Renal Cell Carcinoma emerging therapies
• Advanced Renal Cell Carcinoma Market Dynamics: Advanced Renal Cell Carcinoma market drivers and Advanced Renal Cell Carcinoma market barriers 

Request for Sample PDF Report for Advanced Renal Cell Carcinoma Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services